Luigi Spadafora

GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction, by Luigi Spadafora, Marco Bernardi, Gianluca Campo, Simone Biscaglia, Francesco Versaci et al journals.lww.com/jcardiovascula…

How should real-world muscle safety data shape our confidence in statin alternatives like bempedoic acid? pubmed.ncbi.nlm.nih.gov/41569102 #CardioTwitter #Lipidology #DrugSafety #Pharmacovigilance #RealWorldEvidence

Could epigenetic modulation explain the cardioprotection seen with SGLT2 inhibitors? pubmed.ncbi.nlm.nih.gov/41569049 #CardioTwitter #SGLT2i #CardioEpigenetics #HeartFailure #TranslationalResearch

Can intraoperative drug removal meaningfully change bleeding risk when urgent cardiac surgery can’t wait for antiplatelet washout? pubmed.ncbi.nlm.nih.gov/41642317 #CardioTwitter #CardiacSurgery #Pharmacokinetics #AntiplateletTherapy #MedicalDevices

As triple immune checkpoint regimens move closer to the clinic, are we ready to detect and manage their potential cardiotoxic risks early enough? pubmed.ncbi.nlm.nih.gov/41592248 @istitutotumori #CardioTwitter #CardioOncology #Immunotherapy #CancerResearch #TranslationalScience

Could a subtle shift in molecular structure unlock stronger vascular therapies? pubmed.ncbi.nlm.nih.gov/41343365 #CardioTwitter #VascularBiology #NitricOxide #Pharmacology #TranslationalScience

Cardiovascular safety is becoming a shared responsibility at the heart of effective and sustainable cancer care.    We are grateful to all #ESCardioCRT participants for their structured dialogue and scientific insights supporting the meeting's objectives:   ✅ Advancing a unified approach to cardiovascular safety assessment for modern and emerging cancer therapies, through improved risk stratification, better representation of diverse patient profiles—including sex, age and underlying cardiovascular disease—and alignment of safety endpoints across trials and clinical practice. ✅ Exploring innovative strategies for acute and long-term cardiovascular surveillance, integrating imaging, laboratory and genetic biomarkers with digital health solutions to promote equitable, continuous and high-quality care for patients with cancer and survivors. ✅ Promoting coordinated action across research, regulation and advocacy, laying the groundwork for harmonised data collection and continuity of cardiovascular care across the #cancer trajectory. #cardioonco #cardioonc

Explore the latest advances in #CardioOncology with leading experts in the field🫀 The second COOL Group webinar is coming up, don’t miss it! Join the outstanding faculty: Drs #PietroAmeri, #AlessandraGhigo, & #WouterMeijers Register now: esc365.escardio.org/event/2210 @escardio

⚠️The #ESCardioCRT is a unique event aimed at overcoming communications’ barriers and promote dialogue in #CardioOnc🫀The @escardio is devoted to the CV Health of patients with cancer through the #COCouncil @ESCardioOnco

A New Frontier in Cardio-Oncology: Dual SGLT2i + PCSK9i Therapy? pubmed.ncbi.nlm.nih.gov/41005355 #CardioOncology #SGLT2i #PCSK9i #CardiometabolicHealth #CancerSurvivorship

Can IL-1 Blockade Boost Fitness in Heart Failure at Any Age? pubmed.ncbi.nlm.nih.gov/41071648 #HeartFailure #Inflammation #Anakinra #CardiorespiratoryFitness #IL1Blockade #CardioTwitter

Unlocking a New Shield Against Heart Attack Damage: The Power of sGC pubmed.ncbi.nlm.nih.gov/41082249 #Cardioprotection #IschemiaReperfusion #Mitochondria #OxidativeStress #HeartResearch #CardioTwitter

AI-Powered Mega-Meta-Analysis Reveals Hidden Cardiac Remodeling in Preeclampsia pubmed.ncbi.nlm.nih.gov/41252711 #Preeclampsia #CardiacRemodeling #MetaAnalysis #MaternalHealth #AIinMedicine #CardioTwitter

Can anti-inflammatory therapy like colchicine meaningfully reduce cardiovascular risk, and how comfortable are we with AI helping shape the evidence? pubmed.ncbi.nlm.nih.gov/41406368 #CardioTwitter #CardiovascularResearch #Inflammation #MetaAnalysis #AIinScience

🏆 #JCVPTopPosts – Q4 2025 Here are the most impactful posts from @JCVPonline in the last quarter of 2025: 1️⃣ Intrapericardial Bleomycin: A Promising Option for Malignant Pericardial Effusion x.com/JCVPOnline/sta… 2️⃣ Blocking Inflammation to Boost Heart Fitness: Anakinra’s Promise in Heart Failure x.com/JCVPOnline/sta… 3️⃣ Exercise & Resveratrol: Shielding Kidneys and Vessels from Hypertension x.com/JCVPOnline/sta… 📌 Follow #JCVPTopPosts to stay updated on trending cardiovascular pharmacology research! 🔗 Read more: journals.lww.com/cardiovascular… #CardiovascularPharmacology #BiomedicalResearch #ClinicalResearch #CardioTwitter

🧬➡️🩺 Cardio-oncology still struggles to bridge the gap between translational research and clinical care
In their editorial, Camilli&Abbate highlight soluble neprilysin as a marker of a translational continuum🔬
From bench to bedside: work still to be done🫀 @AbbateAntonio

Perfect Happy New Year! @NEJM @CHassager

Our PRECISE-DAPT Cancer score now validated in a Swedish Cohort (SWEDE-Heart registry) suggesting that the majority of patients with cancer would benefit with short DAPT following ACS / PCI although a few would still benefit from prolonged therapy. We now can better better personalise care in this vulnerable population Thank you to our swedish collaborators for leading on this @SachariasVK @moman_am @DavidErlinge @MoDafaalla

Forza Francesco, Luigi ed Enrico! Un grande in bocca al lupo per le prossime elezioni della Sezione Lazio della Società Italiana di Cardiologia! sicardiologia.it @SIC_CARDIOLOGIA @BURZOTTA_F @LuigiSpadafora @enricoromagnoli

Happy to share my new position: Cardiologist and Assistant Professor of Medicine at the University of Florida College of Medicine-Jacksonville, FL